Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in advanced cancers.

被引：0
|
作者：
Sen, Shiraj
Piha-Paul, Sarina Anne
Kato, Shumei
Karp, Daniel D.
Janku, Filip
Fu, Siqing
Naing, Aung
Pant, Shubham
Tsimberidou, Apostolia Maria
Subbiah, Vivek
Kurzrock, Razelle
Meric-Bernstam, Funda
Hong, David S.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Calif San Diego, La Jolla, CA 92093 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase 1 Program, Houston, TX 77030 USA
[4] Univ Oklahoma, Ctr Hlth Sci, Edmond, OK USA
[5] UCSD Moores Canc Ctr, Ctr Personalized Canc Therapy, La Jolla, CA USA
[6] UCSD Moores Canc Ctr, Div Hematol & Oncol, La Jolla, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.2526
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2526
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers
    Sen, Shiraj
    Kato, Shumei
    Agarwal, Rishi
    Piha-Paul, Sarina
    Hess, Kenneth
    Karp, Daniel
    Janku, Filip
    Fu, Siqing
    Naing, Aung
    Pant, Shubham
    Falchook, Gerald
    Tang, Chad
    Wu, Xifeng
    Ye, Yuanqing
    Tsimberidou, Apostolia
    Subbiah, Vivek
    Kurzrock, Razelle
    Byers, Lauren
    Westin, Shannon
    Lim, JoAnn
    Bean, Stacie
    Bass, Allison
    Ly Nguyen
    Meric-Bernstam, Funda
    Hong, David
    BRITISH JOURNAL OF CANCER, 2018, 118 (11) : 1419 - 1424
  • [2] Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers
    Shiraj Sen
    Shumei Kato
    Rishi Agarwal
    Sarina Piha-Paul
    Kenneth Hess
    Daniel Karp
    Filip Janku
    Siqing Fu
    Aung Naing
    Shubham Pant
    Gerald Falchook
    Chad Tang
    Xifeng Wu
    Yuanqing Ye
    Apostolia Tsimberidou
    Vivek Subbiah
    Razelle Kurzrock
    Lauren Byers
    Shannon Westin
    JoAnn Lim
    Stacie Bean
    Allison Bass
    Ly Nguyen
    Funda Meric-Bernstam
    David Hong
    British Journal of Cancer, 2018, 118 : 1419 - 1424
  • [3] A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases
    Apostolia M. Tsimberidou
    Yang Ye
    Jennifer Wheler
    Aung Naing
    David Hong
    Uchechi Nwosu
    Kenneth R. Hess
    Robert A. Wolff
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 955 - 963
  • [4] A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases
    Tsimberidou, Apostolia M.
    Ye, Yang
    Wheler, Jennifer
    Naing, Aung
    Hong, David
    Nwosu, Uchechi
    Hess, Kenneth R.
    Wolff, Robert A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (04) : 955 - 963
  • [5] Phase I study of nab-paclitaxel and gemcitabine combination in patients with advanced pancreatic cancer
    Drengler, R. L.
    Smith, L. S.
    Wood, T. E.
    Borad, M. J.
    Ramanathan, R. K.
    Laheru, D. A.
    Hidalgo, M.
    Von Hoff, D. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers.
    Shroff, Rachna T.
    Guthrie, Katherine A.
    Scott, Aaron James
    Borad, Mitesh J.
    Goff, Laura Williams
    Matin, Khalid
    Mahipal, Amit
    Kalyan, Aparna
    Javle, Milind M.
    Aghajanian, Carol
    Tan, Benjamin R.
    Cheema, Puneet S.
    Patel, Anuj K.
    Iyer, Renuka V.
    Kelley, Robin Kate
    Thumar, Jaykumar Ranchodbhai
    El-Khoueiry, Anthony B.
    Chiorean, E. Gabriela
    Hochster, Howard S.
    Philip, Philip Agop
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : LBA490 - LBA490
  • [7] Efficacy of sequential perioperative FOLFIRNOX plus gemcitabine nab-paclitaxel for resected pancreatic and periampullary cancers.
    Cen, Putao
    Chan, Kok Hoe
    Wray, Curtis Jackson
    Thosani, Nirav
    Bynon, John
    Rowe, Julie Haewon
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 724 - 724
  • [8] Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial
    Shroff, Rachna T.
    Javle, Milind M.
    Xiao, Lianchun
    Kaseb, Ahmed O.
    Varadhachary, Gauri R.
    Wolff, Robert A.
    Raghav, Kanwal P. S.
    Iwasaki, Michiko
    Masci, Peter
    Ramanathan, Ramesh K.
    Ahn, Daniel H.
    Bekaii-Saab, Tanios S.
    Borad, Mitesh J.
    JAMA ONCOLOGY, 2019, 5 (06) : 824 - 830
  • [9] Phase Ib study of gemcitabine, nab-paclitaxel, and ficlatuzumab in patients with advanced pancreatic cancer
    Perez, Kimberly
    Weekes, Colin D.
    Cleary, James M.
    Abrams, Thomas Adam
    Blaszkowsky, Lawrence Scott
    Enzinger, Peter C.
    Giannakis, Marios
    Goyal, Lipika
    Meyerhardt, Jeffrey A.
    Rubinson, Douglas Adam
    Yurgelun, Matthew B.
    Stonely, Danielle
    Raghavan, Srivatsan
    Bakir, Basil
    Das, Koushik
    Pitarresi, Jason
    Aguirre, Andrew
    Needle, Michael N.
    Rustgi, Anil
    Wolpin, Brian M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [10] Phase I trial of enzalutamide in combination with gemcitabine and nab-paclitaxel in the management of advanced pancreatic cancer
    Kommalapati, A.
    Kim, R.
    Harsha, T. Sri
    Bertels, B.
    Wapinsky, G.
    Burke, N.
    Neuger, A.
    Springett, G.
    Almhanna, K.
    Mahipal, A.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E135 - E135
12345